NCT06104553View on ClinicalTrials.gov

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

SHR-A1912; R-Chemo

SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)

DRUG

SHR-A1912; R-Chemo

SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY